Indeed, tolvaptan in particular proved to be a therapeutic weapon that is specific and effective not only for the treatment of SIADH but also for the conditions of hypervolemic hyponatremia such as CHF, where the primary cause of hyponatremia is increased ADH release [39]. The gene discussed is AVP; the disease is congestive heart failure.